# US 9,937,136 B2 · Methods for treating radiation induced gastrointestinal tract injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,937,136 B2
- Document ID: US9937136B2
- Status: Granted
- Kind: B2
- Application number: 15/036,898
- Filed: 2014-11-16
- Published: 2016-09-29
- Granted: 2018-04-10
- Earliest claimed: 2013-11-17
- Assignees: RDD Pharma Ltd.
- Applicants: Rdd Pharma Ltd.
- Inventors: Nir Barak
- Web page: https://patentgrep.com/patent/US9937136B2

## CPC

- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 39/00: General protective or antinoxious agents
- A61N 2005/1094: {Shielding, protecting against radiation}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of preventing, ameliorating and/or treating radiation induced gastrointestinal tract injury comprising the administration of a therapeutically effective amount of Mesna to a patient are provided. Methods for preventing, treating and/or ameliorating gastrointestinal tract injury induced by radiation therapy, alone or in combination with other therapies for diseases or conditions such as gastrointestinal malignancies, urogenital malignancies, gynecologic malignancies, and osteogenic and other sarcomatous malignancies in which pelvic structures are involved.

## Claims

### Claim 1

A method of treating gastrointestinal tract injury induced by ionizing radiation in a subject comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of sodium 2-sulfanylethanesulfonate (Mesna) and a pharmaceutically acceptable carrier through rectal administration.

### Claim 2 (depends on 1)

The method of claim 1, wherein administering the pharmaceutical composition is performed prior to, during and/or after the subject's exposure to ionizing radiation.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ionizing radiation is a radiation therapy.

### Claim 4 (depends on 2)

The method of claim 2, wherein administering the pharmaceutical composition is performed for at least one day prior to the exposure of the subject to the radiation therapy.

### Claim 5 (depends on 2)

The method of claim 2, wherein administering the pharmaceutical composition is performed for at least five days prior to exposure of the subject to radiation therapy.

### Claim 6 (depends on 2)

The method of claim 2, wherein administering the pharmaceutical composition is performed during the radiation therapy.

### Claim 7 (depends on 2)

The method of claim 2, wherein administering the pharmaceutical composition is performed for at least one day after the cessation of the radiation therapy.

### Claim 8 (depends on 2)

The method of claim 2, wherein administering the pharmaceutical composition is performed for at least fourteen days after the cessation of the radiation therapy.

### Claim 9 (depends on 2)

The method of claim 2, wherein administering the pharmaceutical composition is performed from at least one day prior to first exposure of the subject to the radiation therapy until at least one day after the cessation of radiation therapy.

### Claim 10 (depends on 2)

The method of claim 2, wherein the subject receiving radiation therapy has a condition selected from the group consisting of: a gastrointestinal malignancy, urogenital malignancy, gynecological malignancy and other sarcomatous malignancy.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered to the subject once a day.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered to the subject twice a day, thrice a day or four times a day to the subject.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered daily at a dose ranging from about 1 mg of Mesna/kg body weight to about 600 mg of Mesna/kg body weight.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the gastrointestinal tract injury is acute gastrointestinal tract injury.

### Claim 15 (depends on 14)

The method of claim 14, wherein the injury is colitis or proctitis.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is formulated in a form selected from the group consisting of: enemas, gels, rectal foam, suppositories, tablets, suspensions, emulsions, solutions, capsules, pellets, powders, sachets, cachets, dispersions, aerosols and ointments.

### Claim 17 (depends on 3)

The method of claim 3, wherein the radiation therapy is performed in combination with chemotherapy and/or a surgical procedure.

### Claim 18

A method for preventing gastrointestinal tract injury induced by ionizing radiation in a subject comprising administering, through rectal administration, to the subject a pharmaceutical composition comprising a therapeutically effective amount of sodium 2-sulfanylethanesulfonate (Mesna) and a pharmaceutically acceptable carrier before, during, and/or after exposure the subject to the ionizing radiation.

### Claim 19 (depends on 18)

The method of claim 18, wherein the ionizing radiation is radiation therapy.
